By Thomas M. Burton 

WASHINGTON -- U.S. government scientists are pushing back against calls for one-dose regimens for two Covid-19 vaccines designed to be administered with two shots, saying there isn't enough evidence that a single dose provides long-term protection.

"It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death," Peter Marks, director of the Food and Drug Administration's center that oversees vaccines, told The Wall Street Journal.

The FDA late last year approved a two-dose regimen for vaccines from Moderna Inc. and from a partnership of Pfizer Inc. and BioNTech SE. More recently it approved use of a one-dose regimen for a vaccine from Johnson & Johnson.

Some scientists and lawmakers have called for shifting to a one-dose regimen for all the vaccines, citing preliminary studies showing one shot can be effective. They contend shifting to one shot will allow the U.S. to accelerate the pace of vaccinations.

In a letter to Acting Health and Human Services Secretary Norris Cochran March 2, seven physician members of Congress urged the department "to consider issuing a revised emergency use authorization as soon as possible" that might lead to single-dose use of Pfizer and Moderna vaccines.

"Last week, the U.S. passed a sobering milestone of over 500,000 deaths related to COVID-19," said the letter, signed by lawmakers including Rep. Andy Harris (R, MD.) and Rep. Gregory F. Murphy, (R., NC). "These are staggering statistics, and anything we can do to help prevent further tragedy -- to further protect the public health and safety of the American people -- should be fully employed."

In interviews, senior government scientists at the FDA and the National Institutes of Health said such a shift isn't warranted, saying the evidence used to approve the Pfizer and Moderna vaccines was based on two doses.

These scientists said one dose may offer short-term protection, but the longer-term protection is a question mark.

"You would be flying blind to just use one dose," said one senior scientist and adviser to President Biden. "If you're going to do something else other than follow the studies shown to the FDA, show me that this one-shot effect is durable."

Another senior U.S. government doctor said the durability of the vaccination is especially important when more-resistant strains of Covid, including those from the U.K. and South Africa, are appearing in the U.S.

"We think it's best to get people to as high a level of immunity as possible," the doctor said.

The doctor added that the pace of vaccinations is accelerating with the recent decision by Merck to help produce the J&J vaccine.

"We're going to have a good supply of vaccines very soon," the doctor said.

Representatives of Pfizer and Moderna didn't immediately respond to requests for comment Saturday. Pfizer has previously said it doesn't have data regarding the single-dose approach, and Moderna has previously said it isn't studying the issue.

(More to Come)

Write to Thomas M. Burton at tom.burton@wsj.com

 

(END) Dow Jones Newswires

March 06, 2021 16:32 ET (21:32 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.